USPTO serial 88715931
RETHYMIC
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 23, 2021
- Examiner
- HACK, ANDREA R
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with RETHYMIC?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $399*
Plus Government fees of $325
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
OSAKA, JP
SUMITOMO PHARMA SWITZERLAND GMBH
BASEL, CH
Basel, CH
Basel, CH
Basel, CH
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Allison Strickland Rickettes
Allison Strickland Rickettes FROSS ZELNICK LEHRMAN & ZISSU, P.C.151 WEST 42ND STREET, 17TH FLOORNEW YORK, NY 10036UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for human use for the treatment of pediatric congenital athymia and thymus gland diseases, disorders and conditions, and immune deficiency related thereto; pharmaceutical preparations for human use, namely, tissue-based regenerative therapy to treat pediatric congenital athymia and thymus gland diseases, disorders and conditions, and immune deficiency related thereto; biologic preparations for medical and therapeutic purposes for the treatment of pediatric congenital athymia and thymus gland diseases, disorders and conditions, and immune deficiency related thereto; biologic preparations for medical and therapeutic purposes, namely, tissue-based regenerative therapy to treat pediatric congenital athymia and thymus gland diseases, disorders and conditions, and immune deficiency related thereto | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by SUMITOMO PHARMA CO., LTD.
- Other trademarks owned by SUMITOMO PHARMA SWITZERLAND GMBH
- Other trademarks owned by Enzyvant Therapeutics GmbH
- Other trademarks owned by Enzyvant Therapeutics GmbH
- Other trademarks owned by Enzyvant Therapeutics GmbH
- Other trademarks in Class 005
- Similar marks named RETHYMIC
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 3, 2026 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Mar 23, 2026 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Mar 18, 2026 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Mar 23, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 5, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 5, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 16, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 2, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 1, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 30, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 30, 2020 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Jun 10, 2020 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jun 10, 2020 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jun 10, 2020 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jun 4, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 3, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 3, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 9, 2020 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 9, 2020 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 9, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 6, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 9, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 9, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 7, 2020 | ALIE | ASSIGNED TO LIE | — |
| Dec 16, 2019 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Dec 11, 2019 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Dec 10, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 9, 2019 | NWAP | NEW APPLICATION ENTERED | — |